{"pmid":32485314,"title":"Persistent SARS-CoV-2 infection and the risk for cancer.","text":["Persistent SARS-CoV-2 infection and the risk for cancer.","The current SARS-CoV-2 has put significant strain on healthcare services worldwide due to acute COVID-19. However, the potential long-term effects of this infection haven't been extensively discussed. We hypothesize that SARS-CoV-2 may be able to cause persistent infection in some individuals, and should this be the case, that in a few years we may see a rise in cancer incidence due to carcinogenic effects of this coronavirus. Non-retroviral RNA viruses such as Coronaviridae have been shown to cause persistent infection in hosts. Empirical evidence of viral genomic material shedding weeks after apparent clinical and laboratorial resolution of COVID-19 may be an indirect proof for persistent viral infection. Furthermore, tropism towards certain immune-privileged territories may facilitate immune evasion by this virus. Structural homology with SARS-CoV-1 indicates that SARS-CoV-2 may be able to directly impair pRb and p53, which are key gatekeepers with tumor suppressor functions. Additionally, COVID-19 features preeminent inflammatory response with marked oxidative stress, which acts as both as initiator and promotor of carcinogenesis. Should there be a carcinogenic risk associated with SARS-CoV-2, the implications for public health are plenty, as infected patients should be closely watched during long periods of follow-up. Additional investigation to establish or exclude the possibility for persistent infection is paramount to identify and prevent possible complications in the future.","Med Hypotheses","Alpalhao, Miguel","Ferreira, Joao Augusto","Filipe, Paulo","32485314"],"abstract":["The current SARS-CoV-2 has put significant strain on healthcare services worldwide due to acute COVID-19. However, the potential long-term effects of this infection haven't been extensively discussed. We hypothesize that SARS-CoV-2 may be able to cause persistent infection in some individuals, and should this be the case, that in a few years we may see a rise in cancer incidence due to carcinogenic effects of this coronavirus. Non-retroviral RNA viruses such as Coronaviridae have been shown to cause persistent infection in hosts. Empirical evidence of viral genomic material shedding weeks after apparent clinical and laboratorial resolution of COVID-19 may be an indirect proof for persistent viral infection. Furthermore, tropism towards certain immune-privileged territories may facilitate immune evasion by this virus. Structural homology with SARS-CoV-1 indicates that SARS-CoV-2 may be able to directly impair pRb and p53, which are key gatekeepers with tumor suppressor functions. Additionally, COVID-19 features preeminent inflammatory response with marked oxidative stress, which acts as both as initiator and promotor of carcinogenesis. Should there be a carcinogenic risk associated with SARS-CoV-2, the implications for public health are plenty, as infected patients should be closely watched during long periods of follow-up. Additional investigation to establish or exclude the possibility for persistent infection is paramount to identify and prevent possible complications in the future."],"journal":"Med Hypotheses","authors":["Alpalhao, Miguel","Ferreira, Joao Augusto","Filipe, Paulo"],"date":"2020-06-03T11:00:00Z","year":2020,"_id":"32485314","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.mehy.2020.109882","keywords":["coronavirus","infections","neoplasms","pandemics","risk"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1668704334345404416,"score":9.490897,"similar":[{"pmid":32330293,"title":"Persistent viral RNA positivity during recovery period of a patient with SARS-CoV-2 infection.","text":["Persistent viral RNA positivity during recovery period of a patient with SARS-CoV-2 infection.","As an emerging infectious disease, the clinical course and virological course of SARS-CoV-2 infection remain to be further investigated. In this case report, we described a case of SARS-CoV-2 infection with clinical course more than two months. This patient had recovered from the pneumonia after treatment. The viral RNA of throat swabs became negative and the viral specific antibodies were produced during recovery period. However, the viral RNA reappeared and additionally persisted in throat swabs for more than 40 days. In addition, the viral RNA was detected in multiple types of specimens with extremely high titers in the saliva. In conclusion, these findings indicate that SARS-CoV-2 can cause a long clinical course. The coexistence of viral RNA and viral specific antibodies may imply an immune evasion of SARAS-CoV-2 from host's immune system. This article is protected by copyright. All rights reserved.","J Med Virol","Yang, Jian-Rong","Deng, Dao-Ting","Wu, Nan","Yang, Bin","Li, Hong-Juan","Pan, Xiao-Ben","32330293"],"abstract":["As an emerging infectious disease, the clinical course and virological course of SARS-CoV-2 infection remain to be further investigated. In this case report, we described a case of SARS-CoV-2 infection with clinical course more than two months. This patient had recovered from the pneumonia after treatment. The viral RNA of throat swabs became negative and the viral specific antibodies were produced during recovery period. However, the viral RNA reappeared and additionally persisted in throat swabs for more than 40 days. In addition, the viral RNA was detected in multiple types of specimens with extremely high titers in the saliva. In conclusion, these findings indicate that SARS-CoV-2 can cause a long clinical course. The coexistence of viral RNA and viral specific antibodies may imply an immune evasion of SARAS-CoV-2 from host's immune system. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Yang, Jian-Rong","Deng, Dao-Ting","Wu, Nan","Yang, Bin","Li, Hong-Juan","Pan, Xiao-Ben"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32330293","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1002/jmv.25940","keywords":["coronavirus","sars-cov-2","saliva","virus shedding"],"topics":["Case Report"],"weight":1,"_version_":1666138494704025601,"score":189.63397},{"pmid":31981224,"pmcid":"PMC7166547","title":"Coronavirus infections and immune responses.","text":["Coronavirus infections and immune responses.","Coronaviruses (CoVs) are by far the largest group of known positive-sense RNA viruses having an extensive range of natural hosts. In the past few decades, newly evolved Coronaviruses have posed a global threat to public health. The immune response is essential to control and eliminate CoV infections, however, maladjusted immune responses may result in immunopathology and impaired pulmonary gas exchange. Gaining a deeper understanding of the interaction between Coronaviruses and the innate immune systems of the hosts may shed light on the development and persistence of inflammation in the lungs and hopefully can reduce the risk of lung inflammation caused by CoVs. In this review, we provide an update on CoV infections and relevant diseases, particularly the host defense against CoV-induced inflammation of lung tissue, as well as the role of the innate immune system in the pathogenesis and clinical treatment.","J Med Virol","Li, Geng","Fan, Yaohua","Lai, Yanni","Han, Tiantian","Li, Zonghui","Zhou, Peiwen","Pan, Pan","Wang, Wenbiao","Hu, Dingwen","Liu, Xiaohong","Zhang, Qiwei","Wu, Jianguo","31981224"],"abstract":["Coronaviruses (CoVs) are by far the largest group of known positive-sense RNA viruses having an extensive range of natural hosts. In the past few decades, newly evolved Coronaviruses have posed a global threat to public health. The immune response is essential to control and eliminate CoV infections, however, maladjusted immune responses may result in immunopathology and impaired pulmonary gas exchange. Gaining a deeper understanding of the interaction between Coronaviruses and the innate immune systems of the hosts may shed light on the development and persistence of inflammation in the lungs and hopefully can reduce the risk of lung inflammation caused by CoVs. In this review, we provide an update on CoV infections and relevant diseases, particularly the host defense against CoV-induced inflammation of lung tissue, as well as the role of the innate immune system in the pathogenesis and clinical treatment."],"journal":"J Med Virol","authors":["Li, Geng","Fan, Yaohua","Lai, Yanni","Han, Tiantian","Li, Zonghui","Zhou, Peiwen","Pan, Pan","Wang, Wenbiao","Hu, Dingwen","Liu, Xiaohong","Zhang, Qiwei","Wu, Jianguo"],"date":"2020-01-26T11:00:00Z","year":2020,"_id":"31981224","source":"PubMed","week":"20204|Jan 20 - Jan 26","doi":"10.1002/jmv.25685","keywords":["chemokine","coronavirus","cytokines","inflammation","interferon"],"locations":["Coronaviruses","Coronaviruses"],"topics":["Transmission","Mechanism","Treatment"],"weight":1,"_version_":1666138490926006272,"score":160.12192},{"pmid":32484958,"title":"Clearance and Persistence of SARS-CoV-2 RNA in COVID-19 patients.","text":["Clearance and Persistence of SARS-CoV-2 RNA in COVID-19 patients.","COVID-19 patients may be discharged based on clinical resolution of symptoms, and evidence for viral RNA clearance from the upper respiratory tract. Understanding the SARS-CoV-2 viral clearance profile is crucial to establish a re-testing plan on discharge and ending isolation of patients. We aimed to evaluate the number of days that a patient needed to achieve undetectable levels of SARS-CoV-2 in upper respiratory tract specimens (nasopharyngeal swab and/or an oropharyngeal swab). The clearance and persistence of viral RNA was evaluated in two groups of positive patients: those who achieved two negative RT-PCR tests and those who kept testing positive. Patients were organized thereafter in two subgroups, mild illness patients discharged home and inpatients who had moderate to severe illness. Results from RT-PCR tests were then correlated with results from the evaluation of the immune response. The study evidenced that most patients tested positive for more than two weeks and that persistence of viral RNA is not necessarily associated with severe disease but may result from a weaker immune response instead. This article is protected by copyright. All rights reserved.","J Med Virol","Carmo, Analia","Pereira-Vaz, Joao","Mota, Vanda","Mendes, Alexandra","Morais, Celia","da Silva, Andreia Coelho","Camilo, Elisabete","Pinto, Catarina Silva","Cunha, Elizabete","Pereira, Janet","Coucelo, Margarida","Martinho, Patricia","Correia, Lurdes","Marques, Gilberto","Araujo, Lucilia","Rodrigues, Fernando","32484958"],"abstract":["COVID-19 patients may be discharged based on clinical resolution of symptoms, and evidence for viral RNA clearance from the upper respiratory tract. Understanding the SARS-CoV-2 viral clearance profile is crucial to establish a re-testing plan on discharge and ending isolation of patients. We aimed to evaluate the number of days that a patient needed to achieve undetectable levels of SARS-CoV-2 in upper respiratory tract specimens (nasopharyngeal swab and/or an oropharyngeal swab). The clearance and persistence of viral RNA was evaluated in two groups of positive patients: those who achieved two negative RT-PCR tests and those who kept testing positive. Patients were organized thereafter in two subgroups, mild illness patients discharged home and inpatients who had moderate to severe illness. Results from RT-PCR tests were then correlated with results from the evaluation of the immune response. The study evidenced that most patients tested positive for more than two weeks and that persistence of viral RNA is not necessarily associated with severe disease but may result from a weaker immune response instead. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Carmo, Analia","Pereira-Vaz, Joao","Mota, Vanda","Mendes, Alexandra","Morais, Celia","da Silva, Andreia Coelho","Camilo, Elisabete","Pinto, Catarina Silva","Cunha, Elizabete","Pereira, Janet","Coucelo, Margarida","Martinho, Patricia","Correia, Lurdes","Marques, Gilberto","Araujo, Lucilia","Rodrigues, Fernando"],"date":"2020-06-03T11:00:00Z","year":2020,"_id":"32484958","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1002/jmv.26103","keywords":["covid-19","rt-pcr","sars-cov-2"],"topics":["Diagnosis"],"weight":1,"_version_":1668532114697486336,"score":145.07376},{"pmid":32406369,"title":"SARS-CoV-2 Shedding from Asymptomatic Patients: Contribution of Potential Extrapulmonary Tissue Reservoirs.","text":["SARS-CoV-2 Shedding from Asymptomatic Patients: Contribution of Potential Extrapulmonary Tissue Reservoirs.","The ongoing pandemic COVID-19, caused by SARS-CoV-2, has already resulted in more than 3 million cases and more than 200,000 deaths globally. Significant clinical presentations of COVID-19 include respiratory symptoms and pneumonia. In a minority of patients, extrapulmonary organs (central nervous system, eyes, heart, and gut) are affected, with detection of viral RNA in bodily secretions (stool, tears, and saliva). Infection of such extrapulmonary organs may serve as a reservoir for SARS-CoV-2, representing a potential source of viral shedding after the cessation of respiratory symptoms in recovered patients or in asymptomatic individuals. It is extremely important to understand this phenomenon, as individuals with intermittent virus shedding could be falsely identified as reinfected and may benefit from ongoing antiviral treatment. The potential of SARS-CoV-2 infection to rapidly disseminate and infect extrapulmonary organs is likely mediated through the nonstructural and accessory proteins of SARS-CoV-2, which act as ligands for host cells, and through evasion of host immune responses. The focus of this perspective is the extrapulmonary tissues affected by SARS-CoV-2 and the potential implications of their involvement for disease pathogenesis and the development of medical countermeasures.","Am J Trop Med Hyg","Kalkeri, Raj","Goebel, Scott","Sharma, Guru Dutt","32406369"],"abstract":["The ongoing pandemic COVID-19, caused by SARS-CoV-2, has already resulted in more than 3 million cases and more than 200,000 deaths globally. Significant clinical presentations of COVID-19 include respiratory symptoms and pneumonia. In a minority of patients, extrapulmonary organs (central nervous system, eyes, heart, and gut) are affected, with detection of viral RNA in bodily secretions (stool, tears, and saliva). Infection of such extrapulmonary organs may serve as a reservoir for SARS-CoV-2, representing a potential source of viral shedding after the cessation of respiratory symptoms in recovered patients or in asymptomatic individuals. It is extremely important to understand this phenomenon, as individuals with intermittent virus shedding could be falsely identified as reinfected and may benefit from ongoing antiviral treatment. The potential of SARS-CoV-2 infection to rapidly disseminate and infect extrapulmonary organs is likely mediated through the nonstructural and accessory proteins of SARS-CoV-2, which act as ligands for host cells, and through evasion of host immune responses. The focus of this perspective is the extrapulmonary tissues affected by SARS-CoV-2 and the potential implications of their involvement for disease pathogenesis and the development of medical countermeasures."],"journal":"Am J Trop Med Hyg","authors":["Kalkeri, Raj","Goebel, Scott","Sharma, Guru Dutt"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32406369","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.4269/ajtmh.20-0279","topics":["Treatment","Mechanism"],"weight":1,"_version_":1666802845269098496,"score":143.22775},{"pmid":32498686,"title":"Immunologic aspects of characteristics, diagnosis, and treatment of coronavirus disease 2019 (COVID-19).","text":["Immunologic aspects of characteristics, diagnosis, and treatment of coronavirus disease 2019 (COVID-19).","On March 11, 2020, the World Health Organization declared the worldwide spread of the infectious disease COVID-19, caused by a new strain of coronavirus, SARS-CoV-2, as a pandemic. Like in all other infectious diseases, the host immune system plays a key role in our defense against SARS-CoV-2 infection. However, viruses are able to evade the immune attack and proliferate and, in susceptible individuals, cause severe inflammatory response known as cytokine storm, particularly in the lungs. The advancement in our understanding of the mechanisms underlying the host immune responses promises to facilitate the development of approaches for prevention or treatment of diseases. Components of immune system, such as antibodies, can also be used to develop sensitive and specific diagnostic methods as well as novel therapeutic agents. In this review, we summarize our knowledge about how the host mounts immune responses to infection by SARS-CoV-2. We also describe the diagnostic methods being used for COVID-19 identification and summarize the current status of various therapeutic strategies, including vaccination, being considered for treatment of the disease.","J Biomed Sci","Chang, Feng-Yee","Chen, Hsiang-Cheng","Chen, Pei-Jer","Ho, Mei-Shang","Hsieh, Shie-Liang","Lin, Jung-Chung","Liu, Fu-Tong","Sytwu, Huey-Kang","32498686"],"abstract":["On March 11, 2020, the World Health Organization declared the worldwide spread of the infectious disease COVID-19, caused by a new strain of coronavirus, SARS-CoV-2, as a pandemic. Like in all other infectious diseases, the host immune system plays a key role in our defense against SARS-CoV-2 infection. However, viruses are able to evade the immune attack and proliferate and, in susceptible individuals, cause severe inflammatory response known as cytokine storm, particularly in the lungs. The advancement in our understanding of the mechanisms underlying the host immune responses promises to facilitate the development of approaches for prevention or treatment of diseases. Components of immune system, such as antibodies, can also be used to develop sensitive and specific diagnostic methods as well as novel therapeutic agents. In this review, we summarize our knowledge about how the host mounts immune responses to infection by SARS-CoV-2. We also describe the diagnostic methods being used for COVID-19 identification and summarize the current status of various therapeutic strategies, including vaccination, being considered for treatment of the disease."],"journal":"J Biomed Sci","authors":["Chang, Feng-Yee","Chen, Hsiang-Cheng","Chen, Pei-Jer","Ho, Mei-Shang","Hsieh, Shie-Liang","Lin, Jung-Chung","Liu, Fu-Tong","Sytwu, Huey-Kang"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32498686","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1186/s12929-020-00663-w","keywords":["adaptive immunity","antibody-dependent enhancement","covid-19","cytokine storm","innate immunity","sars-cov","sars-cov-2","vaccine"],"topics":["Treatment","Diagnosis","Mechanism"],"weight":1,"_version_":1668804508719775744,"score":141.70406}]}